Aurobindo Pharma Share Price Target Forecast 2022, 2023, 2025, 2030

10 NOVEMBER 2021

Aurobindo Pharma’s stock has been upgraded to a ‘buy’ by a global brokerage.

In afternoon trade on November 10, Aurobindo Pharma’s stock climbed 3% to Rs 698, following global brokerage company CLSA upgraded the stock from “outperform” to “buy,” with a target price of Rs 830 per share, up 19%. With the addition of Rs.

“The company’s profit fell 13% year over year and is 5% below our forecast.” However, revenue in the United States surprised pleasantly, increasing by 11% year over year.

Antiretroviral (ARV) medicine sales fell sharply in the third quarter. It said that research and development activities for high-penetration-barrier goods were developing nicely.

CLSA, on the other hand, decreased its EPS forecast for FY22-24 by 2-4 percent.

On November 8, the pharma company reported a 13.69 percent drop in its consolidated net profit for the July-September quarter, to Rs 696.71 crore, due to decreased revenues in growing markets and its anti-retroviral division.

According to a regulatory filing, Aurobindo Pharma made a net profit of Rs 807.25 crore in the previous fiscal year’s corresponding period.

During the period under review, total revenue from operations was Rs 5,941.92 crore. In the same period a year ago, it was Rs 6,483.44 crore.

“Business performance was strong across most segments, aided by a gradual pick-up in demand and gradual market share growth,” Aurobindo Pharma said. Cost pressures on some key raw materials, as well as higher logistics costs, had an impact on profitability. N Govindarajan, MD, stated.

Credit Suisse has upgraded the stock to “outperform,” but has lowered the target price to Rs 1,110 per share from Rs 1,130. It has lowered its EPS expectations for FY22, FY23, and FY24 by 5%, 3%, and 5%, respectively.

The price is being disclosed in the injection business, according to the brokerage firm. It stated the injectables division accounted for 25% of profits and that it may re-rate the shares.

The company is rated “Buy” by Goldman Sachs, however the target price has been cut to Rs 860 per share from Rs 930. It has lowered its EPS forecasts for FY 2012-24 by up to 7%, owing to reduced topline and margin growth.

The stock was trading at Rs 697 at 12.36 p.m., up Rs 20.05 or 2.96 percent. It has traded between a high of Rs 706.80 and a low of Rs 678.60 during the day.

The stock traded with a volume of 217,297 shares, up 50.52 percent from its five-day average of 144,366 shares.

Moneycontrol.com is the source for this information.


23 AUGUST 2021

Sharekhan: Aurobindo Pharma Share Price Target 2022; Buy For Rs 915

Sharekhan is optimistic on Aurobindo Pharma and offers a Buy rating on the company with a target price of Rs 915 in its research report dated August 13, 2021.

Aurobindo Pharma (Aurobindo) reported a poor performance in Q1FY22, with results falling short of expectations. For the US company, certain headwinds have surfaced, including increased price erosion and channel inventory buildup, which are projected to remain at least in the short run. Efforts to establish a foothold in specialised sectors like as biosimilars, cancer, and injectables might be growth drivers in the long run, but headwinds in the US industry are projected to impede growth in the near term.

Outlook

The stock is trading at a P/E of 12.4x and 10.8x its FY22E and FY23E EPS, respectively, on CMP, which is a good price. With a revised PT of Rs 915, we maintain our BUY rating.

Moneycontrol.com is the source for this information.


10 JUNE 2021

Sharekhan: Aurobindo Pharma Share Price Target 2022; Buy For Rs 1185

In its Research Report dated May 31, 2021, Sharekhan gives a Buy rating for Aurobindo Pharma with a Target Price of Rs.1185.

The company in the United States and Europe is likely to maintain its strong growth momentum, owing to anticipated traction in the injectable area, new features, a solid product pipeline, and a modest uptake in complicated generics. In addition, the vaccine production plant, which is projected to be operational by the end of July 2021, would provide additional growth opportunities and boost the topline. The company’s primary advantages include improved growth potential, improved earnings clarity, and a healthy financial sheet.

Outlook

With a revised PT of Rs 1,185, we maintain our Buy rating on Aurobindo Pharma.

Moneycontrol.com is the source for this information.


Disclaimer: The views and investment tips expressed by investment expert on Stock consultant bihar are Sourced From Brokerage Firms Research Reports & Market Experts Opinion. We advises users to consult your investment advisor before taking any decisions. Our Website Contain Demat Account & Algo Trading affliate Link. If You’ll Register Through Our Link We May Get Profit.

More Share Price Target Updates:

We will be happy to hear your thoughts

Leave a reply

Stock Consultant Bihar
Logo